Synonym
CEP2563; CEP 2563; CEP-2563
IUPAC/Chemical Name
L-Lysyl-beta-alanine 9(S),12(R)-Epoxy-10(S)-methoxy-9-methyl-1-oxo-2,3,9,10,11,12-hexahydro-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-ylmethyl ester dihydrochloride
InChi Key
WHZMBBYMAAAWBF-XUHOPPJLSA-N
InChi Code
InChI=1S/C36H42N6O6.2ClH/c1-36-13-6-16-41-26-8-5-9-28(43)32(26)31-24-19-39-18-23(24)30-22-11-10-21(48-36)17-27(22)42(36,46-2,34(30)33(31)41)20-47-29(44)12-15-40-35(45)25(38)7-3-4-14-37;;/h6,8,10-11,13,18-19,21,25H,3-5,7,9,12,14-17,20,37-38H2,1-2H3,(H,40,45);2*1H/b13-6-;;/t21-,25-,36-;;/m0../s1
SMILES Code
O=C(OCN12(OC)[C@@](C)(O3)/C=C\CN4C5=C1C(C6=C2C[C@]3([H])C=C6)=C7C(C5=C8C(CCC=C84)=O)=CN=C7)CCNC([C@H](CCCCN)N)=O.[H]Cl.[H]Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
727.68
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Undevia SD, Vogelzang NJ, Mauer AM, Janisch L, Mani S, Ratain MJ. Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors. Invest New Drugs. 2004 Nov;22(4):449-58. PubMed PMID: 15292715.
2: Strock CJ, Park JI, Rosen M, Dionne C, Ruggeri B, Jones-Bolin S, Denmeade SR, Ball DW, Nelkin BD. CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growth. Cancer Res. 2003 Sep 1;63(17):5559-63. PubMed PMID: 14500395.
3: Ho R, Eggert A, Hishiki T, Minturn JE, Ikegaki N, Foster P, Camoratto AM, Evans AE, Brodeur GM. Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res. 2002 Nov 15;62(22):6462-6. PubMed PMID: 12438236.
4: Ruggeri BA, Miknyoczki SJ, Singh J, Hudkins RL. Role of neurotrophin-trk interactions in oncology: the anti-tumor efficacy of potent and selective trk tyrosine kinase inhibitors in pre-clinical tumor models. Curr Med Chem. 1999 Sep;6(9):845-57. Review. PubMed PMID: 10495355.
5: Hudkins RL, Iqbal M, Park CH, Goldstein J, Herman JL, Shek E, Murakata C, Mallamo JP. Prodrug esters of the indolocarbazole CEP-751 (KT-6587). Bioorg Med Chem Lett. 1998 Jul 21;8(14):1873-6. PubMed PMID: 9873450.
